For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zac ...

Key Takeaways GILD stock has surged 27.2% in six months, outpacing its industry, sector, and the S&P 500 index. FDA approval of Yeztugo, the first twice-yearly PrEP, strengthens GILD's HIV portfolio and market edge. New liver drug Livdelzi and rising earnings estimates support GILD's growth and dividend sustainability.Shares of Gilead Sciences, Inc. (GILD) have gained 27.2% in the past six months against the industry’s decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in th ...

Group 1 - The "One Big Beautiful Bill Act" includes over $1 trillion cuts to Medicaid, impacting millions of vulnerable Americans and threatening healthcare providers [2] - Medicaid represents a smaller portion of drugmakers' revenue in the U.S. and globally, with lower reimbursement rates compared to Medicare and commercial insurance [3][4] - Future revenue loss from Medicaid is considered a marginal negative for drugmakers, although some companies are more exposed to the Medicaid market than others [4] Group 2 - Vertex Pharmaceuticals and Gilead are more reliant on Medicaid, with Medicaid accounting for 25% of Vertex's U.S. revenue and 22% of Gilead's domestic sales [5] - Medicaid constitutes 23% of Vertex's sales from cystic fibrosis medicines, which are critical revenue drivers for the company [6]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Gilead Sciences (GILD) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Gilead Sciences is a member of the Medical sector. This group includes 987 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different sector groups. ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Gilead Sciences, Inc. and its officers or directors [1] Company Developments - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns related to decreases in CD4+ T-cell and absolute lymphocyte counts in trial participants [3] - Following the announcement of the clinical hold, Gilead's stock price decreased by $2.91, or 2.58%, closing at $110.09 per share on the same day [3] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Explore the exciting world of Gilead Sciences (GILD 0.79%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of May 28, 2025. The video was published on Jul. 1, 2025. ...

Strategic Transformation & Growth - Gilead is making meaningful progress on strategic transformation with a strong 2023 execution, leading to a catalyst-rich 2024[5, 11, 28, 65] - The company's pipeline has grown by 88% since 2019, positioning it to deliver 10+ new transformative therapies by the end of 2030[18, 19] - Gilead's base business has returned to consistent growth, with an expected 7-8% year-over-year growth in 2023 driven by HIV and Oncology[21, 22] Oncology - Gilead is accelerating its oncology business, aiming for >$3 billion/year[7, 13, 30, 67] - Oncology revenue has grown significantly, reaching ~$3 billion in FY23, representing ~12% of total revenue compared to 2% in FY19[36] - Trodelvy programs reinforce pan-tumor potential, with >30 active or planned trials and >30,000 patients treated[40, 41] - In 1L mNSCLC, Trodelvy plus pembrolizumab demonstrated a strong 69% ORR in PD-L1 TPS>50% and 44% ORR in PD-L1 TPS<50% in the Phase 2 EVOKE-02 trial[48] - Yescarta is the 1 cell therapy in 2L+ LBCL with long-term, 5-year OS of 43% in 3L LBCL and delivered >6,000 cell therapies to patients in 2023[54] HIV - Gilead has a leading HIV portfolio poised for durable growth[9, 15, 32, 69] - Biktarvy is a global leader in HIV treatment, with >47% U S market share in Q3 2023 and projected U S and EU LOE in 2033[72, 73] - The company has an industry-leading HIV development portfolio with 10 clinical programs with lenacapavir[75, 76] - Gilead anticipates 5 potential new HIV product launches by 2030 in treatment & PrEP[17, 71, 78]

Commercial Execution & Market Opportunity - Kite has a broad global ATC footprint with unrivaled patient reach across 420+ ATCs in 25+ countries[14, 34] - The cell therapy market has significant untapped potential, with opportunities to drive market growth in Europe, where 2L+ class share is approximately 20%[38, 41] - Kite's global commercial strategy aims to grow class share by bringing treatment closer to patients and breaking down referral barriers[43] - The company is advancing its portfolio into $40 billion+ markets, including lymphoma & leukemia ($10B-$12B), multiple myeloma ($15B-$20B), and autoimmune diseases ($15B-$20B)[20, 21] Manufacturing Excellence - Kite boasts an industry-leading 14-day turnaround time in the U S for Yescarta and a 96% manufacturing success rate[14, 10] - The company has >24,000 manufacturing capacity by 2026 and >1 million square feet of manufacturing and R&D space[103, 104] - Kite is targeting a biologics product gross margin of approximately 80% in the U S by 2030 through operational excellence and cost improvements[136] - Plans are rapidly advancing for anito-cel manufacturing, leveraging Kite's existing capabilities to achieve similar turnaround times and success rates to Yescarta[137, 140] Clinical Development & Pipeline - Yescarta demonstrates statistically significant overall survival (OS) vs Salvage ± HDCT + ASCT in 2L LBCL, with 43% of patients alive at 5 years in 3L+ LBCL[47] - In ZUMA-7, Yescarta showed a 27% reduction in the risk of death (OS HR 0 726, p=0 0168) and a >4x median EFS in 2L LBCL[197] - The company is developing KITE-753, a CD19/CD20 dual-targeting CAR T with a rapid manufacturing process (3 days) to preserve T cell stemness[228, 231]

Core Insights - Gilead Sciences, Inc. (GILD) received FDA approval for lenacapavir, branded as Yeztugo, a twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg [1][7][10] - Yeztugo is the first and only twice-yearly PrEP option available in the United States, representing a significant advancement in HIV prevention [1][10] - The approval was based on late-stage studies, PURPOSE 1 and PURPOSE 2, which demonstrated that ≥99.9% of participants who received Yeztugo remained HIV-negative [2][8] Company Performance - Year to date, GILD shares have increased by 18.6%, contrasting with a 4% decline in the industry [4] - The approval of Yeztugo enhances Gilead's HIV portfolio, especially as its other prevention drug, Truvada, faces generic competition [12] Competitive Landscape - Yeztugo's long-acting dosing aims to improve PrEP uptake by addressing adherence challenges and stigma associated with daily oral medications [7][10] - Gilead's flagship drug, Biktarvy, holds over 51% of the treatment market share in the United States, indicating strong market positioning [11] - The approval of Yeztugo is expected to catalyze uptake among historically underserved populations, providing a competitive advantage over daily oral pills [11][10] Regulatory and Market Developments - Yeztugo was granted Breakthrough Therapy Designation and has also received validation from the European Medicines Agency for marketing authorization [9] - The approval of long-acting injectable forms of PrEP, such as Yeztugo and ViiV Healthcare's Apretude, indicates a growing trend in HIV prevention strategies [13][14]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3][8] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales [4] - The Growth Score emphasizes a company's financial health and future growth potential, analyzing projected and historical earnings and cash flow [5] - The Momentum Score helps investors capitalize on price trends, utilizing recent price changes and earnings estimate shifts [6] - The VGM Score combines all three Style Scores, providing a comprehensive assessment of stocks based on value, growth, and momentum [7] Zacks Rank and Performance - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in stock selection, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [10][11] Company Spotlight: Gilead Sciences - Gilead Sciences specializes in developing treatments for HIV and other diseases, with total sales from its HIV franchise reaching $19.6 billion in 2024, reflecting an 8% year-over-year growth [12] - Gilead holds a 3 (Hold) Zacks Rank and a VGM Score of A, with a Momentum Style Score of B, indicating potential for upward movement [13][14] - Recent analyst revisions for Gilead's earnings estimates have been positive, with the Zacks Consensus Estimate for fiscal 2025 increasing to $7.92 per share and an average earnings surprise of 16.5% [13]